168 related articles for article (PubMed ID: 35616744)
1. Incidence of Occult Breast Cancer in Carriers of BRCA1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated?
Wong SM; Ferroum A; Apostolova C; Alhassan B; Prakash I; Basik M; Boileau JF; Meterissian S; Aleynikova O; Wong N; Foulkes WD
Ann Surg Oncol; 2022 Oct; 29(11):6660-6668. PubMed ID: 35616744
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
Kaas R; Verhoef S; Wesseling J; Rookus MA; Oldenburg HS; Peeters MJ; Rutgers EJ
Ann Surg; 2010 Mar; 251(3):488-92. PubMed ID: 20134318
[TBL] [Abstract][Full Text] [Related]
3. The value of breast MRI in high-risk patients with newly diagnosed breast cancer to exclude invasive disease in the contralateral prophylactic mastectomy: Is there a role to choose wisely patients for sentinel node biopsy?
Freitas V; Crystal P; Kulkarni SR; Ghai S; Bukhanov K; Escallon J; Scaranelo AM
Cancer Med; 2016 Jun; 5(6):1031-6. PubMed ID: 26992816
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Cancer and Role of Sentinel Lymph Node Biopsy in BRCA Mutation Carriers Undergoing Prophylactic Mastectomies.
Fat SC; Weed C; Samaha Y; Chung A; Boyle MK; Giuliano A; Ray E; Amersi F
Am Surg; 2023 Oct; 89(10):4066-4071. PubMed ID: 37184070
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic mastectomy and occult malignancy: Surgical and imaging considerations.
Thompson JL; Sinco BR; McCaffrey RL; Chang AE; Sabel MS; Dossett LA; Hughes TM; Jeruss JS
J Surg Oncol; 2023 Jan; 127(1):18-27. PubMed ID: 36069388
[TBL] [Abstract][Full Text] [Related]
6. The Use of Sentinel Lymph Node Biopsy in
Câmara S; Pereira D; André S; Mira B; Vaz F; Oom R; Marques JC; Leal de Faria J; Rodrigues Dos Santos C
Int J Breast Cancer; 2018; 2018():1426369. PubMed ID: 29507815
[TBL] [Abstract][Full Text] [Related]
7. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
8. Is Sentinel Lymph Node Biopsy Necessary in Patients who Undergo Prophylactic Mastectomy?
Madan V; Mamounas EP
Clin Breast Cancer; 2023 Feb; 23(2):231-236. PubMed ID: 36575101
[TBL] [Abstract][Full Text] [Related]
9. Routine prophylactic sentinel lymph node biopsy is not indicated in women undergoing prophylactic mastectomy.
Czyszczon IA; Roland L; Sahoo S
J Surg Oncol; 2012 Jun; 105(7):650-4. PubMed ID: 22213101
[TBL] [Abstract][Full Text] [Related]
10. Is routine sentinel lymph node biopsy indicated in women undergoing contralateral prophylactic mastectomy? Magee-Womens Hospital experience.
Soran A; Falk J; Bonaventura M; Keenan D; Ahrendt G; Johnson R
Ann Surg Oncol; 2007 Feb; 14(2):646-51. PubMed ID: 17122987
[TBL] [Abstract][Full Text] [Related]
11. Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy?
McLaughlin SA; Stempel M; Morris EA; Liberman L; King TA
Cancer; 2008 Mar; 112(6):1214-21. PubMed ID: 18257089
[TBL] [Abstract][Full Text] [Related]
12. Residual glandular tissue (RGT) in BRCA1/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies.
Grinstein O; Krug B; Hellmic M; Siedek F; Malter W; Burke C; Schmutzler R; Maintz D; Rhiem K
Surg Oncol; 2019 Jun; 29():126-133. PubMed ID: 31196476
[TBL] [Abstract][Full Text] [Related]
13. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
14. Sentinel lymph node biopsy for risk-reducing mastectomy.
Burger A; Thurtle D; Owen S; Mannu G; Pilgrim S; Vinayagam R; Pain S
Breast J; 2013; 19(5):529-32. PubMed ID: 23865803
[TBL] [Abstract][Full Text] [Related]
15. Contralateral breast cancer and tumor recurrence in BRCA1/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy.
Allué Cabañuz M; Domingo Bretón M; Chóliz Ezquerro J; Arribas Del Amo MD; Güemes Sánchez AT
Cir Esp (Engl Ed); 2020 Dec; 98(10):612-617. PubMed ID: 32505558
[TBL] [Abstract][Full Text] [Related]
16. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
17. Indications for sentinel lymph node biopsy in the setting of prophylactic mastectomy.
Laronga C; Lee MC; McGuire KP; Meade T; Carter WB; Hoover S; Cox CE
J Am Coll Surg; 2009 Dec; 209(6):746-52; quiz 800-1. PubMed ID: 19959044
[TBL] [Abstract][Full Text] [Related]
18. How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?
Garstka M; Henriquez A; Kelly BN; Webster A; Khubchandani JA; Hughes K; Nguyen A; Oseni T; Specht M; Coopey SB; Gadd MA; Smith BL
Ann Surg Oncol; 2021 Oct; 28(10):5657-5662. PubMed ID: 34296361
[TBL] [Abstract][Full Text] [Related]
19. Detecting occult malignancy in prophylactic mastectomy: preoperative MRI versus sentinel lymph node biopsy.
Black D; Specht M; Lee JM; Dominguez F; Gadd M; Hughes K; Rafferty E; Smith B
Ann Surg Oncol; 2007 Sep; 14(9):2477-84. PubMed ID: 17587091
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic mastectomy in patients at high risk: is there a role for sentinel lymph node biopsy?
Murthy V; Chamberlain RS
Clin Breast Cancer; 2013 Jun; 13(3):180-7. PubMed ID: 23357305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
